If you hold any biotech stocks in your portfolio, then it’s time for a gut check. Share prices in this high-risk/high-reward group posted their biggest one-week loss in recent memory, leading investors to figure out if it’s time to get out now… or to commit more funds. How bad was the carnage? The SPDR S&P Biotech ETF (NYSE: XBI) slid nearly 10% on the week, and for many individual stocks, the erosion was far more severe. #-ad_banner-#Cancer-focused biotech Exelixis saw its shares plunge on poor clinical testing data, but all of these other stocks fell out for seemingly… Read More
If you hold any biotech stocks in your portfolio, then it’s time for a gut check. Share prices in this high-risk/high-reward group posted their biggest one-week loss in recent memory, leading investors to figure out if it’s time to get out now… or to commit more funds. How bad was the carnage? The SPDR S&P Biotech ETF (NYSE: XBI) slid nearly 10% on the week, and for many individual stocks, the erosion was far more severe. #-ad_banner-#Cancer-focused biotech Exelixis saw its shares plunge on poor clinical testing data, but all of these other stocks fell out for seemingly no explicable reason. Actually, there was a negative catalyst impacting this whole group: Congress recently questioned a move by Gilead Sciences (Nasdaq: GILD) to price a new hepatitis C drug at more than $1,000 per pill. Many investors quickly concluded that new drugs in development from other biotech firms may not fetch the high reimbursement rates that analysts had been suggesting. To be sure, few drugs in development will be priced quite that boldly. (Indeed, Gilead subsequently relented and suggested that many insurers will get 20% to 30% discounts from that list price.) Yet the issue reminds investors… Read More